Kiniksa (KNSA) Pharmaceuticals was granted FDA orphan designation for its treatment of pericarditis , according to a post to the agency’s website.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: